156 related articles for article (PubMed ID: 38012799)
1. Clinical outcomes up to 9 years after [
Collij LE; Farrar G; Zwan M; van de Giessen E; Ossenkoppele R; Barkhof F; Rozemuller AJM; Pijnenburg YAL; van der Flier WM; Bouwman F
Alzheimers Res Ther; 2023 Nov; 15(1):207. PubMed ID: 38012799
[TBL] [Abstract][Full Text] [Related]
2. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
[TBL] [Abstract][Full Text] [Related]
3. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of [
Leuzy A; Savitcheva I; Chiotis K; Lilja J; Andersen P; Bogdanovic N; Jelic V; Nordberg A
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1276-1286. PubMed ID: 30915522
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
[TBL] [Abstract][Full Text] [Related]
6. Visual assessment of [
Collij LE; Salvadó G; Shekari M; Lopes Alves I; Reimand J; Wink AM; Zwan M; Niñerola-Baizán A; Perissinotti A; Scheltens P; Ikonomovic MD; Smith APL; Farrar G; Molinuevo JL; Barkhof F; Buckley CJ; van Berckel BNM; Gispert JD; ;
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2169-2182. PubMed ID: 33615397
[TBL] [Abstract][Full Text] [Related]
7. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic impact of [
Zwan MD; Bouwman FH; Konijnenberg E; van der Flier WM; Lammertsma AA; Verhey FR; Aalten P; van Berckel BN; Scheltens P
Alzheimers Res Ther; 2017 Jan; 9(1):2. PubMed ID: 28093088
[TBL] [Abstract][Full Text] [Related]
9. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology.
Thal DR; Beach TG; Zanette M; Heurling K; Chakrabarty A; Ismail A; Smith AP; Buckley C
Alzheimers Dement; 2015 Aug; 11(8):975-85. PubMed ID: 26141264
[TBL] [Abstract][Full Text] [Related]
10. Quantification of [
Collij LE; Salvadó G; de Wilde A; Altomare D; Shekari M; Gispert JD; Bullich S; Stephens A; Barkhof F; Scheltens P; Bouwman F; van der Flier WM
Alzheimers Dement; 2023 Jun; 19(6):2397-2407. PubMed ID: 36478646
[TBL] [Abstract][Full Text] [Related]
11. Is there a difference in regional read [
Farrar G; Molinuevo JL; Zanette M
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1299-1308. PubMed ID: 30863934
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Accuracy of Amyloid versus
Lesman-Segev OH; La Joie R; Iaccarino L; Lobach I; Rosen HJ; Seo SW; Janabi M; Baker SL; Edwards L; Pham J; Olichney J; Boxer A; Huang E; Gorno-Tempini M; DeCarli C; Hepker M; Hwang JL; Miller BL; Spina S; Grinberg LT; Seeley WW; Jagust WJ; Rabinovici GD
Ann Neurol; 2021 Feb; 89(2):389-401. PubMed ID: 33219525
[TBL] [Abstract][Full Text] [Related]
13. Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [
Hanseeuw BJ; Malotaux V; Dricot L; Quenon L; Sznajer Y; Cerman J; Woodard JL; Buckley C; Farrar G; Ivanoiu A; Lhommel R
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):302-310. PubMed ID: 32601802
[TBL] [Abstract][Full Text] [Related]
14. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
[TBL] [Abstract][Full Text] [Related]
15. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
[TBL] [Abstract][Full Text] [Related]
16. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.
de Wilde A; van der Flier WM; Pelkmans W; Bouwman F; Verwer J; Groot C; van Buchem MM; Zwan M; Ossenkoppele R; Yaqub M; Kunneman M; Smets EMA; Barkhof F; Lammertsma AA; Stephens A; van Lier E; Biessels GJ; van Berckel BN; Scheltens P
JAMA Neurol; 2018 Sep; 75(9):1062-1070. PubMed ID: 29889941
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
18. An exploratory efficacy study of the amyloid imaging agent [(18)F]flutemetamol in Japanese Subjects.
Senda M; Yamamoto Y; Sasaki M; Yamane T; Brooks DJ; Farrar G; McParland B; Heurling K
Ann Nucl Med; 2015 Jun; 29(5):391-9. PubMed ID: 25874747
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study.
Boccardi M; Altomare D; Ferrari C; Festari C; Guerra UP; Paghera B; Pizzocaro C; Lussignoli G; Geroldi C; Zanetti O; Cotelli MS; Turla M; Borroni B; Rozzini L; Mirabile D; Defanti C; Gennuso M; Prelle A; Gentile S; Morandi A; Vollaro S; Volta GD; Bianchetti A; Conti MZ; Cappuccio M; Carbone P; Bellandi D; Abruzzi L; Bettoni L; Villani D; Raimondi MC; Lanari A; Ciccone A; Facchi E; Di Fazio I; Rozzini R; Boffelli S; Manzoni L; Salvi GP; Cavaliere S; Belotti G; Avanzi S; Pasqualetti P; Muscio C; Padovani A; Frisoni GB;
JAMA Neurol; 2016 Dec; 73(12):1417-1424. PubMed ID: 27802513
[TBL] [Abstract][Full Text] [Related]
20. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
